Persistent Symptoms After Lyme Disease | Rodolico Health

What We Know, What We Don’t, and How We Can Help

Most people diagnosed with Lyme disease recover completely following appropriate antibiotic treatment. However, a small proportion continue to experience symptoms for months after the infection has been successfully treated.

These persistent symptoms are known as Post-Treatment Lyme Disease Syndrome (PTLDS). You may also hear the term Chronic Lyme Disease, although most medical organisations prefer the term PTLDS to describe persistent symptoms following appropriately treated Lyme disease.

At Rodolico Health, we recognise that persistent symptoms following Lyme disease can be distressing and disabling. At the same time, we believe patients deserve clear, evidence-based information about what is currently known—and where important uncertainties remain.

What is Lyme disease?

Lyme disease is a bacterial infection transmitted to humans through the bite of infected ticks. In Europe, it is caused by several closely related Borrelia species and is the most common tick-borne bacterial infection.

The condition often begins with an expanding skin rash called erythema migrans, although not everyone develops or notices one. Other early symptoms may include fever, fatigue, headache, muscle aches and joint pains. If left untreated, Lyme disease can occasionally affect the nervous system, joints or heart. Fortunately, when recognised early, appropriate antibiotic treatment is highly effective, and most people make a full recovery.

What is Post-Treatment Lyme Disease Syndrome?

PTLDS describes persistent symptoms that continue following appropriately treated Lyme disease, when there is no evidence of active infection or another diagnosis that better explains the symptoms.

Although there is no universally accepted diagnostic test or case definition, most research studies describe symptoms that:

• begin during or after documented Lyme disease;
• persist for six months or longer despite recommended antibiotic treatment; and
• cause a significant reduction in day-to-day function.

PTLDS is best thought of as a clinical syndrome rather than a single disease entity.

How common is it?

Estimating how common PTLDS is remains challenging because studies use different definitions and follow-up periods.

Most prospective studies suggest that approximately 5–10% of people treated for Lyme disease experience persistent symptoms lasting six months or longer, although reported estimates vary between studies.

Factors associated with an increased risk include delayed diagnosis, more severe initial illness and disseminated infection.

Fortunately, most patients improve gradually over time, although recovery may be slow.

What causes PTLDS?

This remains an area of active research.

Current evidence suggests that PTLDS is unlikely to result from ongoing active Borrelia infection in most patients who have received appropriate antibiotic treatment.

Instead, researchers are exploring several possible mechanisms, including:

• persistent immune activation following infection;
• inflammatory changes that continue after bacterial clearance;
• alterations in nervous system function;
• changes in pain processing;
• disruption of normal energy metabolism; and
• prolonged recovery following tissue injury sustained during the initial infection.

These mechanisms are not mutually exclusive, and different biological processes may predominate in different individuals.

One important principle is that an infection can act as a trigger rather than an ongoing cause. Once the bacteria have been eliminated, recovery of the immune system, nervous system and affected tissues may take considerably longer than eradication of the infection itself. This principle is increasingly recognised across a number of post-infectious syndromes.

What symptoms can PTLDS cause?

Persistent symptoms vary between individuals but commonly include:

• fatigue;
• widespread muscle or joint pain;
• reduced exercise tolerance;
• cognitive difficulties, often described as “brain fog”;
• headaches;
• sleep disturbance; and
• reduced concentration or memory.

Symptoms frequently fluctuate over time and often overlap with those seen in other post-infectious syndromes.

How is PTLDS diagnosed?

There is no single blood test that confirms PTLDS.

Diagnosis relies on:

• a documented history of Lyme disease;
• completion of appropriate antibiotic treatment;
• persistent symptoms compatible with PTLDS; and
• careful assessment to exclude other medical conditions.

Persistent symptoms such as fatigue, pain and cognitive difficulties are common to many illnesses. A thorough medical assessment remains essential to avoid overlooking other potentially treatable conditions.

Equally important is recognising that persistent symptoms do not necessarily indicate ongoing infection.

Interpreting Lyme disease blood tests

Blood tests for Lyme disease do not detect Borrelia bacteria directly. Instead, they detect antibodies produced by the immune system in response to infection; the medical term for this is serology. A positive antibody test demonstrates evidence of previous exposure, but it does not, on its own, indicate that an infection is currently active. Antibodies commonly remain detectable for months or even years after successful treatment.

Equally, a negative antibody test does not always exclude Lyme disease if testing is performed very early in the course of infection, before the immune system has had time to produce detectable antibodies.

Laboratory testing should support a clinical diagnosis—not replace one. Neither a positive nor a negative test result should be interpreted in isolation.

At Rodolico Health, we place the greatest confidence in results from validated, accredited laboratories using established diagnostic methodologies consistent with recommendations from recognised public health and professional organisations such as the CDC, ECDC and NICE. In the UK, the UK Health Security Agency’s Rare and Imported Pathogens Laboratory (RIPL) is an example of a national reference laboratory providing this standard of testing.

Unfortunately, some laboratories offer alternative Lyme disease tests that have not undergone the same level of independent validation or quality assurance. These tests may produce misleading results and can lead to unnecessary anxiety, additional investigations or treatments that are unlikely to be beneficial.

When reviewing previous Lyme disease investigations, our aim is not to dismiss results obtained elsewhere. Instead, we interpret all available results in the context of your clinical history and, where appropriate, recommend repeat testing through an accredited laboratory using validated methods.

Management and recovery

When Lyme disease is recognised and treated promptly, appropriate antibiotic therapy is highly effective at eradicating the infection and substantially reduces the risk of later complications. This is why recognising the early manifestations of Lyme disease—particularly erythema migrans—is so important.

Equally, antibiotics are not routinely recommended after every tick bite in the absence of clinical features suggestive of Lyme disease. Most tick bites do not result in infection, and unnecessary antibiotic use carries risks including side effects and antimicrobial resistance. Instead, patients should be advised about the early signs and symptoms of Lyme disease and seek medical assessment promptly if these develop.

At present, there is no single treatment that cures PTLDS, and management focuses on improving function, reducing symptom burden and supporting recovery.

Management may include:

• education and reassurance;
• pacing and a gradual return to activity where appropriate;
• optimisation of sleep;
• treatment of headaches or chronic pain;
• rehabilitation tailored to the individual’s symptoms; and
• treatment of co-existing medical conditions.

Current evidence does not support prolonged or repeated courses of antibiotics for most patients with PTLDS. Multiple well-conducted clinical trials have not demonstrated sustained benefit, while prolonged antibiotic therapy carries significant risks, including antimicrobial resistance, allergic reactions, diarrhoea and complications related to intravenous treatment.

The aim of antibiotic treatment is to eradicate the bacterial infection. Persistent symptoms following successful treatment should not automatically be interpreted as evidence that the bacteria remain present. In most patients who have received appropriate therapy, ongoing symptoms are more likely to reflect the body’s response to the previous infection than persistent infection itself.

When should you seek medical assessment?

Medical review is advisable if symptoms:

• persist following treatment for Lyme disease;
• interfere with work or everyday activities;
• are worsening rather than improving; or
• raise concern about an alternative diagnosis.

Assessment aims to identify patients with PTLDS while ensuring that ongoing symptoms are not due to another treatable condition. Although Lyme disease is the best-known tick-borne infection, ticks in Europe can transmit several different infectious agents. Persistent symptoms following a tick bite should therefore always be assessed in the context of the individual’s clinical history, travel history and examination findings.

How Rodolico Health can help

Persistent symptoms following Lyme disease deserve careful, compassionate and evidence-based medical assessment.

Our approach begins by listening carefully to your experience, reviewing the original diagnosis and treatment, considering alternative explanations where appropriate and developing an individualised management plan based on the best available evidence.

Medicine continues to evolve, and many important questions about post-infectious syndromes remain unanswered. We believe patients deserve transparent, evidence-based care that acknowledges both what modern medicine knows and where uncertainty still exists.

Our role is neither to dismiss persistent symptoms nor to promise miracle cures. Instead, we provide careful assessment, evidence-based medicine and honest guidance through what can often be a complex and uncertain recovery.

If you would like to discuss any of the issues raised in this article, you are very welcome to get in touch or book an appointment.

You are also welcome to join our newsletter for monthly health updates and evidence-based guidance.